Elfatih Mohammed Abdallah, Mohammed Osman, Ihsan Mohammed, Ibrahim Bakhit
1Elfatih. A, PhD Medical Laboratory Sciences, Shendi University, Haematology Department. Shendi.
2Mohamed. A, PhD Medical Laboratory Science, Shendi University, Haematology Department. Shendi
3Ihsan.O, Professor of pathology, Faculty of medicine, Alzaiem Alazhari University. Khartoum.
4Ibrahim.Y, PhD Medical Laboratory Science, Shendi University, Histopathology Department. Shendi
Corresponding author: elfatih195@hotmail.com
Abstract
Breast cancer is a major public health problem in both developed and developing countries (1) with more than one million new cases diagnosed annually.(2) Breast cancer remains a common and frequency fatal disease More than (1.2 million) women are diagnosed with breast cancer annually worldwide. In developed countries, most patients (<80%) with breast cancer present with operable disease that can apparently be entirely resected surgically. (3) This is a prospective cross-sectional descriptive study based on laboratory data of (136) patients with breast cancer carried out from (2012-2017) in Nuclear Medicine and Cancer Research centre – Shendi University and Nuclear Medicine and Cancer Research Centre – Aljazeera University, which aimed to evaluate hematinix status in breast cancer patients in Sudan. The investigations were performed on serum sample obtained from venous blood sample drawn in plain container for vitamin B12, folic acid and ferritin by using ELISA techniques.
Regarding the hematinix status in breast cancer patients, the mean of vitamin B12, folic acid and ferritin was (364.6 pg/ml), (7.5 ng/ml) and (189.9 ng/ml) respectively. The study conducted that ferritin level was elevated in breast cancer patients with highly statistical significant differences regarding anemic status, vitamin B12 and folic acid levels were within normal range in study population
Keywords: Breast cancer, Vitamin B12, Folic acid, Ferritin.